Replies to post #521177 on NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

Bullshit. Are we just making up numbers now?! Chris Brown would agree with this narrative.

Shares fell from $2,51 to ~$0,70 the day the TLD data was released.

[biosectinvestor]

This is false.

Shares fell from $2,51 to ~$0,70 the day the TLD data was released. And it has not materially shown ANY higher price for over six months.

Moreover it stayed flat YTD after, generally, with some fluctuation below and above, but generally flat. And before 5/10 it was run up by false hopes loudly proclaimed by many shareholders. I understand the sentiment, but that is the reality. It did not get anywhere near $2.51 however and it went back to where it was before it was pumped.

Optune is an external device. It does not have the same level of complexity for its trials and could statistically and hypothetically predict it’s survival stats and get approved based on PFS, which is often flawed.

NWBO went with Survival, and yes that takes a long time and there were financial challenges during the financial crisis and complexities discovered with immunotherapies during the time of the trial including in other, similar trials. However NWBO has followed the rules and is in the process of applying and has not been rejected. Nor did they violate any FDA rules and they made changes to OS while still blinded, again, consistent with FDA guidelines.

[Roman516]

NWBO stock fell the day of 5/10 based on a number of factors,

1) Preplanned stock blitz to try to drive the price south.
2) Activation of planned blitz prior to the initial start of the presentation.
3) The presentation could have been more focused to illustrate the real OS results.
4) False information from certain individuals.
5) False information from cancer media based on a specific individual'
6) Management should have addressed these issues sooner.
There are other factors that should be on this list including some reserved based on ongoing investigations.

No doubt there are a number of individuals who do not want NWBO to succeed as they continue to post their biased information in the attempts to get investors to dump this stock. However, the fact of the matter is that NWBO product DCVax-L works. The OS data results prove this and there are multiple individuals with real testimonies that have been also revealed. In addition, there are multiple doctors, scientist and professionals are not only impressed but are excited that NWBO's products will in fact more forward. Once again, the advanced manufacturing capabilities "Flaskworks Devices (EDENS)" had received USPTO patent authorization in 03/22. The good news is that the presentation results instantiate support the fact that the OS data is valid. The Advent facility started to ramp up their advanced automation processes as defined, and the goal was to complete this task before the end of the year even with the supply chain issues. However, the supply chain issues were resolved ahead of schedule. In light of all the effort to bring the Advent facility up to speed, it appears this will occur before the end of the year. In all, many are forward to GMP approvals followed by MIA and MA approvals soon afterwards. Yes, progress takes time as NWBO continues to move forward.
IMPO.